aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Fore Biotherapeutics, founded with a mission to revolutionize cancer treatment, is a precision oncology company focused on developing innovative therapies guided by proprietary functional genomics. The company's vision is to compassionately contribute to solving cancer through science and innovation. Fore Biotherapeutics offers a range of genomics-guided cancer therapies, with a market focus on precision oncology, aiming to provide targeted treatments for various cancer types.
Notable figures affiliated with Fore Biotherapeutics include leaders in oncology and genomics research, as well as prominent investors from the biotech sector. The company has achieved significant milestones, including the development of its flagship program, Plixorafenib. Fore Biotherapeutics' impact is marked by its contribution to personalized cancer treatment, offering hope to patients through advanced, targeted therapeutic options.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Cancer Therapies
Technology
Genomics
Tags
Biotech
Model Types
Biotech
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Fore Biotherapeutics founded?
Fore Biotherapeutics was founded in 2011.
Where is Fore Biotherapeutics's headquarters located?
Fore Biotherapeutics's headquarters is located in Philadelphia, PA, US.
When was Fore Biotherapeutics's last funding round?
Fore Biotherapeutics's most recent funding round was for $75M (USD) in August 2023.
How many employees does Fore Biotherapeutics have?
Fore Biotherapeutics has 45 employees as of Feb 4, 2024.
How much has Fore Biotherapeutics raised to-date?
As of July 05, 2023, Fore Biotherapeutics has raised a total of $166.5M (USD) since Aug 23, 2023.
Add Comparison
Total Raised to Date
$166.5M
USD
Last Update Aug 23, 2023
Last Deal Details
$75M
USD
Aug 23, 2023
Series D
Total Employees Over Time
45
As of Feb 2024
Fore Biotherapeutics Address
Philadelphia,
Pennsylvania
19132
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts